LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New COVID-19 Antibody Assay Can Analyze Up to 40,000 Samples per Day Using Serum or Dried Blood

By LabMedica International staff writers
Posted on 24 Sep 2020
Print article
Image: New COVID-19 Antibody Assay Can Analyze Up to 40,000 Samples per Day Using Serum or Dried Blood (Photo courtesy of Neoteryx LLC)
Image: New COVID-19 Antibody Assay Can Analyze Up to 40,000 Samples per Day Using Serum or Dried Blood (Photo courtesy of Neoteryx LLC)
A new COVID-19 antibody assay can analyze up to 40,000 samples per day and is suitable for both serum and dried blood sampling.

The new COVID-19 antibody has been developed by LGC's Immunogenicity Centre of Excellence (Cambridge, UK) and uses serum or capillary blood collected remotely with the Mitra microsampling device from Neoteryx LLC (Torrance, CA, USA). Individuals can be tested for SARS-CoV-2 antibodies by visiting a blood draw center to provide a serum sample via phlebotomy, or by collecting their own blood sample at home using the Mitra device and a simple fingerstick method. The Mitra blood samples can be posted through the regular mail to LGC's Centre of Excellence laboratory for testing, where sample data are processed and reported using the company's custom LIMS system. The assay developed by LGC for SARS-CoV-2 antibody testing achieves specificity of (95% CI) 100% (98.7-100.0) and sensitivity of (95% CI) 98.0% (87.0-99.0) for samples taken 21 days post positive PCR test. Sample results can be reported within 24 hours of sample receipt.

"A real value of remote blood sampling with the Mitra device for testing in LGC's outstanding lab is that people don't have to leave home to learn if they have developed SARS-CoV-2 antibodies," said James Rudge, PhD, Technical Director, Neoteryx. "Our Mitra is designed with volumetric absorptive microsampling, or VAMS technology, which enables virtually anyone to collect a few drops of blood on the device with scientific precision."

"Our assay is suitable for partnering with employers for back to work testing using the self-sampling Mitra device, and therefore does not require a phlebotomist to take the blood sample in a healthcare setting," added LGC's Commercial Director, Michael van der Merwe. "The assay can also support patient stratification for clinical trials and COVID-19 vaccine development. As well as qualitative data, we can also provide semi-quantitative data on the level of antibodies present indicating the magnitude of the immune response."

Related Links:
LGC's Immunogenicity Centre of Excellence
Neoteryx LLC


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-CoV-2 RT-PCR Assay
Reliance SARS-CoV-2 RT-PCR Assay Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more